Monoclonal antibodies

Multiple myeloma
#FDA #GSK #Monoclonal antibodies #Myeloma #Oncology

FDA committee votes against Blenrep combinations for myeloma

The US Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) has voted against the overall benefit/risk profile at GSK’s proposed dosage of Blenrep (belantamab mafodotin-blmf) combinations.   The belantamab mafodotin combinations were evaluated in adults with relapsed or refractory multiple myeloma who have received at least one prior line… Read More

#News #Regulatory

Scientist conducts tests in the lab
#AstraZeneca #Haematology #Monoclonal antibodies #Phase III trial

AZ’s anselamimab fails to meet primary endpoint in amyloidosis trial

High-level results from the Cardiac Amyloid Reaching for Extended Survival (CARES) Phase III clinical programme show that anselamimab did not achieve statistical significance for the primary endpoint compared to placebo in patients with Mayo stages IIIa and IIIb light chain (AL) amyloidosis.   The primary endpoint was defined… Read More

#News

Colon cancer
#China #Colorectal cancer #Monoclonal antibodies #Oncology #Pierre Fabre Laboratories

China approval for colorectal cancer combination treatment

The Chinese authorities have granted a marketing authorisation for Pierre Fabre Laboratories’ Braftovi, in combination with cetuximab, for the treatment of adult patients with BRAFV600E-mutant metastatic colorectal cancer, after prior systemic therapy.  The approval is based on the Phase III BEACON CRC trial, which demonstrated a significant improvement in overall… Read More

#News #Regulatory

Molecular,Model,Of,Antibody
#Antibody #Clinical trials #Haematology #Harvard Medical School #ITP #Monoclonal antibodies #Platelet biology #Takeda

Mezagitamab and the future of ITP treatment

The International Society on Thrombosis and Haemostasis (ISTH) 2025 Congress took place in Washington DC from 21-25 June 2025. At this event, Takeda presented final results from a Phase II trial evaluating mezagitamab (TAK-079), a potential best-in-class anti-CD38 monoclonal antibody (mAb), in patients with persistent or chronic primary immune thrombocytopenia… Read More

#Exclusive Content

Female researcher in a laboratory
#Biologics #Biomanufacturing #Monoclonal antibodies #Phylloceuticals #Plant-based

US company hopes to transform access to advanced biologics

Phylloceuticals has announced the successful production of its first batch of a PD-1 inhibitor monoclonal antibody (mAb) just 12 weeks after initiating operations in its new laboratory space in Rapid City, South Dakota, US.   The company says the achievement marks a potential paradigm shift in how complex… Read More

#News

Monoclonal antibody
#AbbVie #Autoimmune disease #Bi- and trispecifics #Mergers and acquisitions #Monoclonal antibodies #Oncology

AbbVie licenses trispecific antibody in billion-dollar contract

IGI Therapeutics, a wholly owned subsidiary of Ichnos Glenmark Innovation, and AbbVie have announced an exclusive licensing agreement for IGI’s lead investigational asset, ISB 2001, for oncology and autoimmune diseases.  “Multispecifics including trispecific antibodies represent a new frontier in immuno-oncology with the potential to deliver deeper, more durable responses by… Read More

#Business & Investment #News

Bladder
#AstraZeneca #Bladder cancer #European Commission #Monoclonal antibodies #Oncology

EU-approved bladder cancer therapy reduces death risk by 25%

AstraZeneca’s Imfinzi (durvalumab) has been approved in the European Union (EU) for the treatment of adult patients with resectable muscle-invasive bladder cancer (MIBC) in combination with gemcitabine and cisplatin as neoadjuvant treatment.  According to the decision, this treatment should be followed by Imfinzi as monotherapy adjuvant treatment after radical cystectomy (surgery… Read More

#Cancer Research #News #Regulatory

#Drug discovery #eBook #Monoclonal antibodies #Therapeutic Antibodies

The significance of mAbs in drug discovery and development

Monoclonal antibodies (mAbs), thanks to their low toxicity and high specificity, have enjoyed incredible market success across a range of disease categories. This eBook, sponsored by Evotec, examines the challenges, solutions and successes in mAb discovery and development. Download this exclusive eBook to learn more about: The 2025 scientific breakthroughs… Read More

#DDW eBooks #Intelligence

#Antibody engineering #Antibody-based therapeutics #eBook #Monoclonal antibodies #Therapeutic Antibodies

eBook: The significance of mAbs in drug discovery and development

Monoclonal antibodies (mAbs), thanks to their low toxicity and high specificity, have enjoyed incredible market success across a range of disease categories. Of the 2024 top 10 bestselling drugs, half were mAbs, with Merck’s Keytruda (pembrolizumab) in the lead, followed by Abbvie’s Humira (adalimumab), Sanofi and… Read More

#News

Human eye
#AMD #Monoclonal antibodies #Ophthalmology #Outlook Therapeutics #Scottish Medicines Consortium (SMC)

Bevacizumab gamma gets Scottish OK for wet AMD

The Scottish Medicines Consortium (SMC) has approved Lytenava (bevacizumab gamma) for the treatment of wet age-related macular degeneration (wet AMD).   It is the first licensed ophthalmic formulation of bevacizumab for use in treating wet AMD in adults in the EU and the UK and has an initial 10 years of… Read More

#News #Regulatory

Baby on a respirator - RSV
#FDA #Merck #Monoclonal antibodies #Paediatrics #Respiratory syncytial virus

FDA approves Merck’s Enflonsia for RSV prevention

The US Food and Drug Administration (FDA) has approved Enflonsia (clesrovimab-cfor) for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in neonates (newborns) and infants who are born during or entering their first RSV season.   Enflonsia is a preventive, long-acting monoclonal antibody (mAb) designed to provide direct,… Read More

#News #Regulatory

Lung cancer
#European Commission #Lung cancer #Monoclonal antibodies #Oncology

European Commission approves Tevimbra for small cell lung cancer

The European Commission has approved Tevimbra (tislelizumab), in combination with etoposide and platinum chemotherapy, as a first-line treatment for adult patients with extensive-stage small cell lung cancer (ES-SCLC).  The new indication is based on results of RATIONALE-312 study, which demonstrated statistically significant overall survival benefit for patients treated with Tevimbra… Read More

#News #Regulatory

Monoclonal antibody
#Crohn's disease #European Commission #Inflammatory Bowel Disease #Johnson & Johnson #Monoclonal antibodies

New EU approval for Johnson & Johnson’s guselkumab

The European Commission (EC) has approved Tremfya (guselkumab), the first dual-acting IL-23 inhibitor offering both subcutaneous (SC) and intravenous (IV) induction options, for adult patients with moderately to severely active Crohn’s disease.  The approval is based on data which showed that guselkumab induction therapy administered either intravenously (GALAXI 2 and… Read More

#News #Regulatory

ulcerative colitis
#European Commission #Johnson & Johnson #Monoclonal antibodies #Ulcerative colitis (UC)

Guselkumab approved in the EU for ulcerative colitis

The European Commission (EC) has approved a marketing authorisation (MA) for Johnson & Johnson’s Tremfya (guselkumab) for the treatment of adult patients with moderately to severely active ulcerative colitis (UC).  It is approved in patients who had an inadequate response, lost response, or were intolerant to either conventional therapy or… Read More

#News #Regulatory

Monoclonal antibodies
#Monoclonal antibodies #Multiple sclerosis #Phase II trial #Tiziana Life Sciences #University of Massachusetts

UMass joins Phase II trial for multiple sclerosis

The University of Massachusetts (UMass) has begun dosing participants with Tiziana Life Sciences’ lead development candidate, intranasal foralumab, as part of an ongoing Phase II trial in patients with non-active secondary progressive multiple sclerosis (na-SPMS). UMass joins Brigham and Women’s Hospital (BWH), Yale Multiple Sclerosis Center, and Johns… Read More

#News

Melanoma
#Aulos Bioscience #Melanoma #Monoclonal antibodies #Oncology #Phase II trial

Aulos doses first patient in Phase II cohort for melanoma treatment

Aulos Bioscience has dosed its first patient with a combination of AU-007, the anti-PD-1 antibody nivolumab and low-dose, subcutaneous aldesleukin in a Phase II expansion cohort focused on second-line treatment of melanoma.   The new cohort forms part of the company’s Phase I/II clinical trial of AU-007… Read More

#Cancer Research #News